Residual Invasive Breast Cancer
Also known as: Invasive, residual Breast Cancer
Drug | Drug Name | Drug Description |
---|---|---|
DB05773 | Trastuzumab emtansine | An antineoplastic agent and antibody-drug conjugate used to treat HER2-overexpressing breast cancer. |
Drug | Drug Name | Target | Type |
---|---|---|---|
DB05773 | Trastuzumab emtansine | Receptor tyrosine-protein kinase erbB-2 | target |
DB05773 | Trastuzumab emtansine | P-glycoprotein 1 | transporter |
DB05773 | Trastuzumab emtansine | Cytochrome P450 3A4 | enzyme |
DB05773 | Trastuzumab emtansine | Cytochrome P450 3A5 | enzyme |
Drug | Drug Name | Phase | Status | Count |
---|---|---|---|---|
DB00072 | Trastuzumab | 3 | Active Not Recruiting | 1 |
DB14962 | Trastuzumab deruxtecan | 3 | Active Not Recruiting | 1 |
DB05773 | Trastuzumab emtansine | 3 | Active Not Recruiting | 1 |